• / Free eNewsletters & Magazine
  • / My Account
Home>Stocks>CTS Corporation

CTS Corporation

  1. All
  2. Morningstar Articles
  3. Videos
  4. 3rd Party
  5. Investing
  1. Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

    Clinigen Group Further Strengthens Oncology Support Portfolio with Acquisition of Ethyol® (amifostine), from AstraZeneca

  2. CTS Announces Second Quarter 2014 Results

    CTS Announces Second Quarter 2014 Results

  3. Magna Announces Second Quarter and Year to Date Results

    Magna Announces Second Quarter and Year to Date Results

  4. IMRIS receives CE mark for integrating latest generation MR scanners within VISIUS Surgical Theatre in European market

    IMRIS receives CE mark for integrating latest generation MR scanners within VISIUS Surgical Theatre in European market

  5. UPDATE: GM to recall additional 717,950 vehicles

    UPDATE: GM to recall additional 717,950 vehicles

  6. What to Do With Exelon?

    Pepco deal, power prices, capacity markets, carbon caps: It’s been a wild ride for Exelon in 2014.

  7. GM's Bigger Story Is Beyond the Headlines

    The new General Motors is much leaner than its predecessor, and any near-term litigation risk will have little impact on the automaker's 1.85 billion diluted shares.

  8. Changes at GM With Exit of U.S. Treasury and Entrance of New CEO

    Our fair value estimate and moat rating remain intact.

  9. Open Road Ahead for U.S. Autos

    Even after a strong rebound from the market trough in 2009, the U.S. auto sector still has room to run.

  10. The Search for Creative Destruction

    Wasatch's Sam Stewart looks for companies that do things so differently that they can change an industry forever.

Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.